OncoMatch/Clinical Trials/NCT06937905
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
Is NCT06937905 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Standard of Care Chemotherapy and Tarlatamab for neuroendocrine carcinoma.
Treatment: Standard of Care Chemotherapy · Tarlatamab — Based on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Biomarker criteria
Required: DLL3 expression in at least 1% of tumor cells (≥1%)
Expression of DLL3 in at least 1% of tumor cells
Required: EGFR activating mutation
Known EGFR activating mutation for lung NEC [excluded]
Required: ALK rearrangement
Known...ALK...rearrangement for lung NEC [excluded]
Required: ROS1 rearrangement
Known...ROS1 rearrangement for lung NEC [excluded]
Performance status
WHO 0–1
Prior therapy
Must have received: platinum-based chemotherapy — metastatic
Tumor progression following one platinum based line of therapy
Cannot have received: DLL3-targeted therapy
Previous treatment targeting DLL3
Cannot have received: systemic therapy
Exception: Chemotherapy for non-metastatic stage is not considered as first-line if there is a time interval of at least 6 months between the last dose of chemotherapy for non-metastatic stage and the initiation of first-line chemotherapy for metastatic/recurrent disease.
More than one line of systemic therapy in the metastatic setting
Lab requirements
Blood counts
neutrophils count ≥ 1500/mm3; platelets > 100 000/mm3 ; hemoglobin > 9 g/dl
Kidney function
creatinine clearance > 50 ml/min
Liver function
ast and alt < 3 x uln (upper limit of normal) with total bilirubin ≤ 2 × uln except subjects with documented gilbert's syndrome or liver metastasis, who must have ast and alt ≤ 5 x uln and a baseline total bilirubin ≤ 3.0 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify